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Abstract
Background: Although many vaccinia virus proteins have been identified and studied in detail, only
a few studies have attempted a comprehensive survey of the protein composition of the vaccinia
virion. These projects have identified the major proteins of the vaccinia virion, but little has been
accomplished to identify the unknown or less abundant proteins. Obtaining a detailed knowledge
of the viral proteome of vaccinia virus will be important for advancing our understanding of
orthopoxvirus biology, and should facilitate the development of effective antiviral drugs and
formulation of vaccines.
Results: In order to accomplish this task, purified vaccinia virions were fractionated into a soluble
protein enriched fraction (membrane proteins and lateral bodies) and an insoluble protein enriched
fraction (virion cores). Each of these fractions was subjected to further fractionation by either
sodium dodecyl sulfate-polyacrylamide gel electophoresis, or by reverse phase high performance
liquid chromatography. The soluble and insoluble fractions were also analyzed directly with no
further separation. The samples were prepared for mass spectrometry analysis by digestion with
trypsin. Tryptic digests were analyzed by using either a matrix assisted laser desorption ionization
time of flight tandem mass spectrometer, a quadrupole ion trap mass spectrometer, or a
quadrupole-time of flight mass spectrometer (the latter two instruments were equipped with
electrospray ionization sources). Proteins were identified by searching uninterpreted tandem mass
spectra against a vaccinia virus protein database created by our lab and a non-redundant protein
database.
Conclusion: Sixty three vaccinia proteins were identified in the virion particle. The total number
of peptides found for each protein ranged from 1 to 62, and the sequence coverage of the proteins
ranged from 8.2% to 94.9%. Interestingly, two vaccinia open reading frames were confirmed as
being expressed as novel proteins: E6R and L3L.
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Background
Variola virus (smallpox agent) and/or genetically-engi-
neered orthopoxviruses are considered one of the most
significant Category A pathogenic threats for malevolent
use as potential agents of bioterrorism [1]. Due to the bio-
terrorism threat, there is a renewed public interest in the
development of effective anti-poxvirus drug(s) and/or
vaccines for use in treating or preventing human diseases
caused by pathogenic poxviruses. Because the nucleotide
sequence of the variola virus is approximately 90% iden-
tical with that of the vaccinia virus, VV [2], we hypothesize
that VV can act as a model for variola. At present, there are
no effective anti-orthopoxvirus drugs available, and the
Dryvax vaccine used during the eradication campaign is
not considered safe for general use, considering immuno-
Mass analysis of a distinct peptide from the L4R protein using Method 1 (SDS-PAGE + LC-ESI-Q-TOF MS) Figure 1
Mass analysis of a distinct peptide from the L4R protein using Method 1 (SDS-PAGE + LC-ESI-Q-TOF MS) 
Panel A shows the Coomassie blue stained SDS-PAGE gel of the core-enriched fraction and panel B is the membrane-enriched 
fraction. Gel slices that were analyzed by MS are denoted with letters. The full scan mass spectrum (inset of C) displays a dou-
bly charged parent ion at m/z 867.9. The corresponding tandem mass spectrum (C) identifies a peptide of the L4R protein. 
Asterisks (*) denote the loss of ammonia (NH3) or water (H2O).
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Table 1: Vaccinia virion proteins identified in this study. Membrane- and core-enriched fractions were both analyzed by five different 
methods: Method 1 (SDS-PAGE + LC-ESI-Q-TOF MS), Method 2 (SDS-PAGE + LC-ESI-QIT MS), Method 3 (HPLC + LC-ESI-QIT MS), 
Method 4 (LC-ESI-Q-TOF MS), and Method 5 (MALDI-TOF/TOF MS). Identified proteins are listed according to their corresponding 
ORF. The total number of non-redundant peptides and the percent of the protein identified are recorded.
ORF Function/location Ref. Methods # peptides % Coverage
A3L Major core protein [17] 1,2,3,4,5 39 71.6
A4L IMV/P4a associated protein [18] 1,2,3,4,5 16 49.1
A5R RNA pol. subunit [19] 1,4,5 3 29.9
A7L Early transcription factor [20] 1,2,4,5 7 12.7
A10L Major core protein [21] 1,2,3,4,5 62 64.3
A12L Viral structural protein [22] 1,3,4 4 14.6
A13L Membrane phosphoprotein [23] 1,2,3,4,5 6 91.4
A14L Membrane phosphoprotein [23] 1,2,4,5 4 61.1
A15L Core assoc. protein [24] 1,2,3 5 60.2
A16L Myristoylprotein; entry/fusion [25, 26] 1,2,5 4 12.2
A17L IMV membrane prtn [27, 28] 1,2,4,5 4 32.0
A24R RNA pol. subunit [29] 1,2,4,5 26 30.9
A27L IMV membrane prtn [30] 1,2,3,4,5 17 70.0
A29L RNA pol. subunit [31] 2,5 2 8.2
A30L Virion component [32] 2,3,4,5 3 58.4
A33R EEV glycoprotein [33] 1,4,5 2 21.6
A34R EEV glycoprotein [34] 1,2,4 2 23.2
A42R Profilin homolog [35] 1,2,3,4,5 6 51.1
A46R Interact with host IL-1 [36] 1 2 12.6
A56R EEV glycoprtn, hemagglutinin [37] 1,4,5 3 12.4
B5R EEV glycoprotein [38] 4 2 10.4
B22R Serpin (C16L) [39] 1,2,4,5 3 19.9
D1R Capping enzyme subunit [40] 1,2,4,5 15 22.7
D2L virion component [41] 1,2,4,5 9 63.0
D3R virion component [41] 1,2,4,5 8 50.6
D6R Early transcription factor [42] 2,5 7 11.9
D8L IMV membrane protein [43, 44] 1,2,3,4,5 26 89.1
D11L DNA-dependent ATPase [45] 1,2,5 9 17.3
D12L Capping enzyme subunit [46] 1,2,4,5 8 40.4
E1L PolyA polymerase [47, 48] 2,4,5 4 11.1
E3L dsRNA dep. protein kinase [49] 1,5 1 13.2
E4L RNA polymerase [50] 1,2,4,5 5 27.8
E6R unknown 1,2,4,5 20 43.1
E8R Virion component [51, 52] 1,2,4,5 11 57.1
E10R Oxidase [53] 2,3,4,5 2 17.9
E11L Viral core protein [54] 1,2,4,5 2 26.4
F8L Cytosolic protein [55] 3,4,5 4 60.0
F9L Mem. prtn.; similarity to L1R [53] 1,2,3,5 4 22.6
F10L Protein kinase [56, 57] 1,2,5 4 15.7
F13L EEV membrane protein [58] 1,2,4,5 9 32.0
F17R DNA binding phosphoprotein [59] 1,2,3,4,5 9 55.4
G1L metalloproteinase [60] 1,2,4,5 10 19.1
G3L Entry/fusion complex [61] 2,3,4,5 6 41.4
G4L glutaredoxin [62] 2,3,4,5 11 77.4
G7L Core cmpnnt, partners w/A30L [63] 1,2,3,4,5 20 59.8
H1L Protein phosphatase [64] 1,2,3,4,5 10 67.3
H3L Immunodominant protein [65] 1,2,3,4,5 31 79.0
H4L RNA pol. associated protein [66] 1,2,4,5 5 10.6
H5R Membrane phosphoprotein [67] 1,2,3,4,5 8 49.3
I1L encapsidated DNA-binding prtn [68] 1,2,3,4,5 6 20.5
I3L DNA binding phosphoprotein [69, 70] 2,5 3 18.6
I5L Virion component [71] 1,4 5 94.9
I7L Core protein proteinase [72] 2 9 18.4
I8R RNA/DNA-dependant NTPase [73] 4,5 4 8.7
J1R IMV membrane protein [74] 1,2,4,5 5 30.1
J3R Poly(A) polymerase, RNA methyltransferase [48, 75] 1,2,4,5 14 47.4
J4R RNA polymerase [76] 1,2,4 6 38.4
J6R RNA polymerase [76] 1,2,4,5 34 33.9
K4L Homolog to VP37, phoshoplipase D [58, 77] 3,4 4 8.5
L1R IMV membrane protein [78] 2,3,4,5 8 40.8
L3L unknown 1,2,4,5 7 22.9
L4R Major core protein [79] 1,2,3,4,5 25 77.7
O2L Glutaredoxin [80, 81] 1,2,3,4,5 7 70.4Virology Journal 2006, 3:10 http://www.virologyj.com/content/3/1/10
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compromised people, and the complications associated
with this live-attenuated vaccine.
Poxviruses, such as VV, are amongst the largest and most
complex of the eukaryotic DNA viruses and are distin-
guished by replicating exclusively within the cytoplasmic
compartment of infected cells [3]. VV regulates the expres-
sion of more than 250 viral gene products in a temporal
fashion during the viral replicative cycle which results in
at least four infectious forms all of which share the same
intracellular mature virus (IMV) at their center which con-
tains one membrane and a concave brick core. VV proteins
are denoted by their corresponding open reading frame
(ORF). The conventional designation of VV ORF consists
of a Hind III DNA fragment (A-O), followed by the
number of the ORF in that fragment (numbered left to
right), and finally by the direction of the ORF (L or R).
Although the complete genome sequence of VV (strain
Copenhagen) has been available for years [4], there has
been little comprehensive proteomic analysis of the VV
virion described so far. Jensen, et al. identified 13 major
membrane and core proteins of the VV virion using 2-D
gel electrophoresis followed by in-gel trypsin digests and
peptide mass fingerprints for database searching [5].
Using a similar gel-based strategy, three major early pro-
teins associated with the virosomes in VV-infected cells
were identified by Murcia-Nicolas, et al. [6].
In this report we have utilized tandem mass spectrometry
(MS) to analyze the protein composition of the vaccinia
virion. A comprehensive proteome analysis of the protein
composition of the VV virion represents an analytical
challenge as there is no general analytical strategy availa-
ble that is capable of identifying membrane and core pro-
teins, low and high abundant proteins equally well.
Therefore, we have used several analytical strategies to
obtain a large number of high confidence protein identi-
fications. Two different separation strategies [high per-
formance liquid chromatography (HPLC) and sodium
dodecyl sulfate-polyacrylamide gel electophoresis (SDS-
PAGE)] were combined with tandem mass spectrometry.
In addition, a "shotgun" approach with no further separa-
tion was evaluated. For the tandem mass spectrometry,
three different MS instruments were utilized: 1.) a matrix
assisted laser desorption ionization tandem mass spec-
trometer with time-of-flight/time-of-flight optics
(MALDI-TOF/TOF), 2.) a quadrupole-time of flight mass
spectrometer (LC-ESI-Q-TOF), and 3.) a quadrupole ion
trap mass spectrometer (LC-ESI-QIT); the latter two
instruments were equipped with online HPLC and elec-
trospray ionization interfaces [7]. In the process of analyz-
ing the vaccinia virion, we have identified sixty three VV
proteins, two of which have not been reported previously.
Results
Viral fractionation
In order to simplify our analytical strategy, we partitioned
the vaccinia virion into two enriched fractions: a superna-
tant or membrane fraction containing the soluble pro-
teins and a fraction enriched with the cores and insoluble
proteins. The fractionation was assisted by incubating
purified virions in the presence of a reducing agent and
non-ionic detergent. Beta-octylglucopyranoside (OG) was
chosen as the detergent for dissolving the membrane
because in low amounts it does not adversely affect MS
analysis, whereas, conventional detergents such as SDS
and Triton X100 can greatly interfere with HPLC and mass
spectrometric analysis [8]. We tested the efficiency of OG
in separating the virion components and found that the
supernatant and pellet banding patterns on an SDS-PAGE
gel differ (Figure 1A and 1B). Subsequent analysis of this
separation with immunoblot analysis using antibodies to
L1R (membrane protein) and 4b (A10L, core protein)
showed that each fraction was enriched with these pro-
teins (data not shown). Due to the comprehensive nature
of this study, no attempts were made to completely sepa-
rate the soluble membrane proteins from the core pro-
teins.
Identification of VV proteins
Table 1 summarizes the results of our proteomic study.
Tandem mass spectrometry yields peptide sequences,
allowing the search of non-redundant protein databases
to obtain high confidence protein identifications. In total,
over 2716 tandem mass spectra were analyzed to yield
sequence information for 595 non-redundant peptides.
Peptides scores of 40 or greater were considered positive
matches. In rare cases, tandem mass spectra that yielded
scores 20 and 40 were analyzed manually. In order for a
protein to be a "positive" we used the following criteria:
1.) identify greater than 5% of the protein sequence; 2.)
more than one peptide needed to be identified in a single
method, or a single peptide needed to be identified at
least with two different methods. Using these stringent
conditions, sixty three different proteins were identified in
the vaccinia virion. The total number of peptides found
for each protein ranged from 1 to 62 (Table 1, column 5),
and the total sequence coverage of the proteins ranged
from 8.2% to 94.9% (Table 1, column 6). Of the sixty
three proteins identified, 2 are predicted gene products
that have not been shown to be expressed before: E6R and
L3L (Table 1, italicized).
Method 1: SDS-PAGE + LC-ESI-Q-TOF MS
SDS-PAGE was employed to partition the core- and mem-
brane-enriched fractions prior to MS analysis. The two
protein fractions were resolved on a 12.5% SDS-PAGE gel
and stained with Coomassie brilliant blue (Fig 1A and
1B). Each gel was sliced into several sections and each sec-Virology Journal 2006, 3:10 http://www.virologyj.com/content/3/1/10
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tion was subjected to in-gel trypsin digestion as described
in the Methods section. The tryptic digests were analyzed
by LC-ESI-Q-TOF MS. As a typical example of the kind of
data used for peptide identification using MASCOT soft-
ware, the tandem mass spectrum of a peptide originating
from the major core protein, L4R, is shown in Figure 1C.
This spectrum was obtained from the tryptic digest of gel
slice "h" (Fig. 1B). The full scan mass spectrum shows a
peak at m/z 867.9 which represents the doubly charged
ion of a peptide with a molecular mass of 1733.8 Da. Tan-
dem MS of the doubly charged ion at m/z 867.9 yielded a
fragment ion spectrum displaying eleven C-terminal (y-
type) fragment ions and one N-terminal (b-type) frag-
ment ion. Database searching of this tandem mass spec-
trum identified this peptide as ELESYSSSPLQEPIR, the
partial sequence (amino acid [aa] 213–227) of the L4R
protein. This tandem mass spectrum obtained the excel-
lent score of 129. Using this method we obtained 708
spectra, observed 315 peptides and identified 52 proteins.
Method 2: SDS-PAGE + LC-ESI-QIT MS
The tryptic digestions from the excised gel slices were
additionally analyzed on an ion trap mass spectrometer
(LC-ESI-QIT). Using this platform we identified 53 virion
proteins from 1088 spectra corresponding to 417 total
peptides. For example, during the mass spectrometric
analysis of the tryptic digest of gel slice "d" (Fig. 1A) an
ion peak at m/z 831.1 in the full scan mass spectrum was
observed (Fig. 2C inset) which corresponds to a doubly
charged ion of a peptide with molecular mass 1660.2 Da.
The tandem MS of the double charged ion had a good
score of 62 and revealed the sequence for a peptide of the
E6R protein, LGLVLDDYKGDLLVK (aa 470–484). Seven
C-terminal fragment ions, nine N-terminal fragment ions,
and two internal fragments ions (m/z 399.1 [GDLL] and
m/z 527.0 [KGDLL]) were observed for this particular
peptide. E6R is a vaccinia protein that has not been previ-
ously reported.
Method 3: HPLC + LC-ESI-QIT MS
We also employed reverse phase HPLC to fractionate the
proteins prior to MS analysis (Fig. 3A is the enriched core
fraction and Fig. 3B is the enriched membrane fraction).
HPLC separation was well suited for fractionating the sol-
uble proteins, but proved to be more challenging for the
insoluble core proteins. The cores did not completely dis-
solve even when treated with sodium deoxycholate.
Approximately 200 μL of sample (as described in the
Methods section) was loaded onto a 2 × 150 mm C4
reverse phase column, and fractions were collected manu-
Mass analysis of a distinct peptide from the E6R protein using Method 2 (SDS-PAGE + LC-ESI-QIT MS) Figure 2
Mass analysis of a distinct peptide from the E6R protein using Method 2 (SDS-PAGE + LC-ESI-QIT MS) Gel slice 
"d" from the SDS-PAGE of the core-enriched fraction (Fig. 1A) was subjected to an in-gel trypsin digestion, and analyzed by 
LC-ESI-QIT MS. The tandem mass spectrum data, correlating to the full scan mass spectrum (inset, doubly charged parent ion 
at m/z 831.1), reveals a peptide of the E6R protein. Asterisks (*) denote the loss of ammonia (NH3) or water (H2O).
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Mass analysis of a distinct peptide from the L1R protein using Method 3 (HPLC + LC-ESI-QIT MS) Figure 3
Mass analysis of a distinct peptide from the L1R protein using Method 3 (HPLC + LC-ESI-QIT MS). The core- 
(A) and membrane-enriched (B) fractions were resolved on a C4 HPLC column according to the Methods section. Tandem 
mass spectrometric analysis of fraction 59–60 (B, indicated by brackets) produced from a singly charged precursor ion (inset, 
m/z 1289.7), yielded fragment ions which corresponded to a peptide the L1R protein. Asterisks (*) denote the loss of ammonia 
(NH3) or water (H2O).
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ally every 2 minutes between 20 and 80 minutes. Each of
these fractions was subjected to trypsin digestion prior to
analysis by LC-ESI-QIT MS. Using this method we
obtained 367 tandem mass spectra that correlated to 131
total peptides yielding 25 distinct vaccinia virion proteins.
A representative example is shown in Figure 3C. The
membrane sample at 59–60 minutes (Fig. 3B, brackets)
underwent tandem mass spectrometric analysis to reveal a
peptide of the well characterized L1R protein. The full
scan spectrum for this fraction contained an ion at m/z
1289.7 (Fig. 3C, inset) which was used for tandem mass
spectrometry. The fragment ions observed matched the
theoretical fragmentation pattern for a peptide of the L1R
protein (Fig. 3C) encompassing the sequence LEQEANA-
SAQTK, aa 22–33. The ions at m/z 534.1, 605.2, 719.3,
790.4, 1047.3, and 1176.5, are the C-terminal fragment
ions, while the ions at m/z 756.1, 842.6, 914.1, and
1042.4 are the N-terminal fragments. This spectrum
received an acceptable score of 47.
Method 4: LC-ESI-Q-TOF MS
We wanted to analyze the samples without pre-fractiona-
tion to compare the data with thegel fractions (method 1
& 2) and HPLC fractions (method 3). Known as a "shot-
gun" approach, the membrane- and core-enriched frac-
tions were directly digested with trypsin, and analyzed
using LC-ESI-Q-TOF MS. This methodology resulted in
319 tandem mass spectra that matched 202 total peptides,
and identified 53 virion proteins. One exciting example is
the L3L protein (Fig. 4), a protein that has not been
reported before. When the parent ion at m/z 844.5 (Fig. 4,
inset) was fragmented, four C-terminal, five N-terminal,
and four internal fragment ions (m/z 211.1, 302.2, 324.2,
and 415.3) were observed. The respective tandem mass
spectrum had a score of 59. This data was assigned to the
sequence AVGFPLLK (aa 115–122) of the L3L protein.
Method 5: MALDI-TOF/TOF MS
Direct trypsin digests of the membrane- and core-enriched
fractions were also analyzed using MALDI-TOF/TOF MS
to take advantage of complementary ionization tech-
niques [7]. MALDI tandem mass spectrometry generated
234 spectra, correlating to 209 total peptides, and result-
ing in 55 unique virion protein identifications. Of partic-
ular interest is the ion at m/z at 1522.69 in the full scan
mass spectrum (Fig. 5, inset). Tandem mass spectral anal-
ysis of this ion revealed the peptide HTFNLYDDNDIR, the
partial sequence (aa 90–101) of the G3L protein. The tan-
dem mass spectral analysis yielded six C-terminal, and 4
N-terminal fragment ions (Fig. 5), and obtained an aver-
age score of 41.
Mass analysis of a distinct peptide from the L3L protein using Method 4 (LC-ESI-Q-TOF MS) Figure 4
Mass analysis of a distinct peptide from the L3L protein using Method 4 (LC-ESI-Q-TOF MS). The core-enriched 
fraction of the virion was subjected to trypsin digestion, and analyzed by the LC-ESI-Q-TOF mass spectrometer. The full scan 
mass spectrum displays a peak at m/z 844.5 (inset), and corresponding tandem mass spectrum identifies a peptide of the L3L 
protein. Four internal fragments were also identified for the L3L peptide including: PL, GFP, PLL, and GFPL.
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New vaccinia virus proteins
This comprehensive study of the vaccinia virion revealed
two newly observed proteins. Each of these proteins (E6R
and L3L) has not been described previously. The peptides
detected for each of these proteins are listed in Tables 2
and 3.
The E6R ORF is situated between the E5R and E7R genes
and produces a 567 amino acid protein. The predicted
molecular mass and pI of E6R is 66,670 Da and 6.16,
respectively. E6R was identified in fraction "d" of figure
1A, which corresponds to its predicted molecular weight.
Blast searches revealed high homology to orthopoxvirus
proteins [9]. Hydrophobicity plots revealed no specific
region of interest [10]. We observed 19 peptides from the
E6R protein with a confidence scoring range of 17–85.
The identified peptides covered 43.1% of the protein
(Table 2).
We observed 7 peptides for L3L covering 22.9% of the
sequence (Table 3). The L3L protein has a predicted
molecular mass of 40.6 kDa (350 amino acids), and a pre-
dicted pI of 8.91. Its ORF is situated between the L2R and
L4R genes. This protein was identified in fraction "e" and
"f" of Figure 1A. Only poxvirus proteins had homology to
the L3L sequence resulting from Blast searches [9], and
hydrophobicity plots revealed no specific region of inter-
est [10].
Both proteins were found in samples from the core-
enriched fractions of Method 1, 2, 4, and 5. No peptides
from either protein were found in the membrane-
enriched fractions.
Discussion
The goal of this study was to obtain a comprehensive pro-
teomic analysis of the Copenhagen strain of the vaccinia
virus virion. This strain of VV was chosen because it is an
important model strain for variola, and it has been com-
pletely sequenced.
One concern we had was that the predominant proteins
would eclipse the smaller or less abundant proteins when
analyzed by MS. In order to overcome this problem we
fractionated the virion into soluble (membrane) and
insoluble (core) fractions via treatment with detergent
and centrifugation. Further fractionation was achieved
using two procedures: SDS-PAGE and HPLC. The resolu-
tion of viral proteins by SDS-PAGE followed by in-gel
trypsin digestion of gel slices and tandem mass analysis
(LC-ESI-QIT MS) for protein identification had been used
successfully before on other VV proteins [11]. A second
MS analysis was done in parallel with these samples using
LC-ESI-Q-TOF MS. Although both instruments use the
same ionization techniques, the mass analyzers are differ-
ent. Both mass spectrometers identified 49–52 proteins
using this procedure, however, the proteins identified dif-
Mass analysis of a distinct peptide from the G3L protein using Method 5 (MALDI-TOF/TOF) Figure 5
Mass analysis of a distinct peptide from the G3L protein using Method 5 (MALDI-TOF/TOF). The membrane-
enriched fraction of the virion was subjected to trypsin digest, and analyzed by MALDI-TOF/TOF MS. The full scan mass spec-
trum yielded a singly charged ion at m/z 1522.69 (inset). Tandem mass spectrum of the parent ion corresponds to a peptide of 
G3L. Asterisks (*) denote the loss of ammonia (NH3) or water (H2O).
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Table 2: Amino acid sequence of the VV protein E6R and identified peptides Peptides detected from the Method 1 (SDS-PAGE + LC-
ESI-Q-TOF MS), Method 2 (SDS-PAGE + LC-ESI-QIT MS), Method 3 (HPLC + LC-ESI-QIT MS), Method 4 (LC-ESI-Q-TOF MS), and 
Method 5 (MALDI-TOF/TOF MS) are denoted with an asterisk (*). Peptides that are in bold print have been identified by at least one 
of the five methods.
Method MDFIRRKYLIYTVENNIDFLKDDTLSKVNNFTLNHVLALKYLVSNFPQHV
1 ***********************
2 ******************** **********
3
4
5
ITKDVLANTNFFVFIHMVRCCKVYEAVLRHAFDAPTLYVKALTKNYLSFS
1 *** ***********
2 *** ***********
3
4
5
NAIQSYKETVHKLTQDEKFLEVAEYMDELGELIGVNYDLVLNPLFHGGEP
1
2
3
4 ********************************
5
IKDMEIIFLKLFKKTDFKVVKKLSVIRLLIWAYLSKKDTGIEFADNDRQD
1 *************
2
3
4 **
5 **
IYTLFQQTGRIVHSNLTETFRDYIFPGDKTSYWVWLNESIANDADIVLNR
1 **********
2 ********
3
4
5 *********************
HAITMYDKILSYIYSEIKQGRVNKNMLKLVYIFEPEKDIRELLLEIIYDI
1 ************
2 ********
3
4
5
PGDILSIIDAKNDDWKKYFISFYKANFINGNTFISDRTFNEDLFRVVVQI
1 *****
2 ********
3
4 ********
5 *****
DPEYFDNERIMSLFSTSAADIKRFDELDINNSYISNIIYEVNDITLDTMD
1 **********************
2
3
4
5 *********
DMKKCQIFNEDTSYYVKEYNTYLFLHESDPMVIENGILKKLSSIKSKSKR
1
2
3
4
5
LNLFSKNILKYYLDGQLARLGLVLDDYKGDLLVKMINHLKSVEDVSAFVR
1 ***************
2 ****** *******************************
3
4Virology Journal 2006, 3:10 http://www.virologyj.com/content/3/1/10
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fered (Fig. 6). Complementary to SDS-PAGE for protein
fractionation, reverse phase HPLC was used (Method 3).
Due to the encountered difficulties with the insolubility
of the viral cores, only the major core proteins were iden-
tified (A3L and A10L) from the core-enriched fraction,
resulting in a low total number of proteins identified with
this procedure (25 versus 49–54 for the other methods,
Fig. 6). Support for this notion is obtained by the study
reported by Zachertowska, et al. in which the pooling of
fractions from 5 HPLC runs resulted in the identification
of only 6 proteins of the myxoma virion [12]. Recognizing
this limitation we utilized multiple methods to obtain a
more comprehensive catalog of the virion constituents. In
order to complete this study, we felt it important to ana-
lyze the membrane- and core-enriched samples without
separation prior to trypsin digestion. We used two differ-
ent mass spectrometers to analyze the in-solution digests:
MALDI-TOF/TOF MS and LC-ESI-Q-TOF MS. This "shot-
gun" strategy resulted in a lower number of total spectra
and identified a lower number of peptides, but yielded a
comparable number of protein identifications (54 and 52,
respectively, Fig. 6).
A summary of the number of proteins found versus the
method used to detect them is shown in Figure 6. There is
a high degree of overlap between the methods; notewor-
thy is that 15 proteins were identified by all 5 methods.
Another 20 proteins were identified using methods 1, 2, 4,
and 5; this is most likely due to the lack of data for the
core-enriched fraction using the HPLC pre-separation pro-
cedure (method 3). The majority of the VV proteins iden-
tified in this study were observed in 3 or more methods
(85.7%), underscoring the complementarity of the differ-
ent approaches used.
The current functional annotation of the VV genome is
described in the following articles: a minireview by Pao-
letti,  et al [4], describing an update on the vaccinia
genome, and the Poxviridae chapter in Fields Virology
written by Bernard Moss [3]. Both of these articles
describe the organization of the entire genome of the vac-
cinia virion, and the known functionality of the various
vaccinia proteins. Moss describes there being 47 known
ORFs that express proteins of the vaccinia virion including
membrane proteins as well as core constituents. It is inter-
esting to note that we found 41 of the known virion com-
ponents. Of the 25 non-enzymatic components only one
was not identified – the D13L protein which has been
linked to rifampicin resistance. Of the 22 enzymatic virion
components 17 were identified in this study. Two of the
missed proteins include D7R and G5.5R which are the
two smallest subunits of the RNA polymerase. Although
these two components were not identified, the other six
RNA polymerase subunits were identified (A5R, A24R,
A29L, E4L, J4R and J6R). The remaining three known vir-
ion enzymes that were not identified in this study include:
A18R (DNA-dependent ATPase), B1R (Protein Kinase 1)
and H6R (DNA Topoisomerase 1). Several factors might
contribute to the lack of data for these proteins including:
the size of the protein, the hydrophobicity of a protein,
and the absolute amount of a protein in the virion. In gen-
eral, very hydrophobic proteins and low abundance pro-
teins are commonly underrepresented in proteomic-type
studies. Also, very small proteins are frequently missed. In
an effort to overcome at least in part these inherent limi-
tations of comprehensive proteomic studies, we com-
bined different protein fractionation methods with
"shotgun" approaches. In addition, to ensure that the
highest level of confidence for peptide identification and
protein coverage for the current study, the "shotgun"
digests were analyzed by two different ionization tech-
niques, ESI and MALDI, taking advantage of the comple-
mentarity of these ionization techniques [7].
5
FSTDKNPSILPSLIKTILASYNISIIVLFQRFLRDNLYHVEEFLDKSIHL
1 ************
2
3
4
5
TKTDKKYILQLIRHGRS
1
2
3
4
5 *******
Table 2: Amino acid sequence of the VV protein E6R and identified peptides Peptides detected from the Method 1 (SDS-PAGE + LC-
ESI-Q-TOF MS), Method 2 (SDS-PAGE + LC-ESI-QIT MS), Method 3 (HPLC + LC-ESI-QIT MS), Method 4 (LC-ESI-Q-TOF MS), and 
Method 5 (MALDI-TOF/TOF MS) are denoted with an asterisk (*). Peptides that are in bold print have been identified by at least one 
of the five methods. (Continued)Virology Journal 2006, 3:10 http://www.virologyj.com/content/3/1/10
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Some recently reported proteins that have been shown to
be associated with the core include: A15L, A30L, E11L,
G1L, G7L, H1L and J1R – all of which were identified in
our analysis. We also found membrane proteins (F9L,
F10L, and E8R) and cytosolic proteins (A16L, E10R, F8L,
G4L, and I3L). The remaining proteins identified by this
study included A42R, A46R, B22R, E3L, and K4L. The
types of VV proteins identified in this study are summa-
rized in Figure 7.
Conclusion
This study represents the first steps toward a widespread
identification of the viral protein constituents that make
up the structurally complex VV virion. Although not
quantitative, this approach has confirmed the presence of
most known virion proteins and identified new viral pro-
teins for the first time. Defining the VV proteome is a sig-
nificant scientific challenge but successful completion of
this goal will be useful for understanding the biology of
orthopoxviruses.
Methods
Materials
Media and supplements were purchased from Invitrogen
(Carlsbad, CA). Dithiothreitol (DTT), Tris, N-ethylmor-
pholine, trifluoroacetic acid (TFA), formic acid, α-cyano-
Table 3: Amino acid sequence of the VV protein L3L and identified peptides Peptides detected from the Method 1 (SDS-PAGE + LC-
ESI-Q-TOF MS), Method 2 (SDS-PAGE + LC-ESI-QIT MS), Method 3 (HPLC + LC-ESI-QIT MS), Method 4 (LC-ESI-Q-TOF MS), and 
Method 5 (MALDI-TOF/TOF MS) are denoted with an asterisk (*). Peptides that are in bold print have been identified by at least one 
of the five methods.
Method MNTRTDVTNDNIDKNPTKRGDRNIPGRNERFNDQNRFNNDRPRPKPRLQP
1 **************
2 **************
3
4 **************
5
NQPPKQDNKCREENGDFINIRLCAYEKEYCNDGYLSPAYYMLKQVDDEEM
1
2
3
4
5
SCWSELSSLVRSRKAVGFPLLKAAKRISHGSMLYFEQLKNSKVVKLTPQV
1
2
3
4 ********
5
KCLNDTVIFQTVVILYSMYKRGIYSNEFCFDLVSIPRTNIVFSVNQLMFN
1
2
3
4
5
ICTDILVVLSICGNRLYRTNLPQSCYLNFIHGHETIARRGYEHSNYFFEW
1
2
3
4
5 ***********
LIKNHISLLTKQTMDILKVKKKYATGAPVNRLLEPGTLVYVPKEDYYFIG
1
2 ***************
3
4 *******
5 ***
ISLTDVSISDNVRVLFSTDGIVLEIEDFNIKHLFMAGEMFVRSQSSTIIV
1
2
3
4 ******************
5 *****************************Virology Journal 2006, 3:10 http://www.virologyj.com/content/3/1/10
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4-hydroxycinnamic acid (HCCA), guanidine hydrochlo-
ride and β-Octylglucopyranoside (OG) were purchased
from Sigma (St. Lois, MO). HPLC grade acetonitrile (AcN)
was purchased from Fisher Scientific (Pittsburg, PA) and
the lyophilized sequencing-grade trypsin from Promega
(Madison, WI). General use water was generated by a
Milli-Q water purification system (Millipore, Bellerica,
MA)
Virion purification and fractionation
Vaccinia virus (Copenhagen strain) was propagated as
described by Hruby et al[13], and modified in the follow-
ing way: ten 150 mm dishes of 80% confluent BSC40 cells
were infected at a multiplicity of infection of 0.1 plaque
forming units (pfu)/cell. The infected cells were harvested
and subjected to homogenization. Purified virus was
obtained through a side-band-pull from a buoyant
sucrose density gradient. This purified virus was pelleted
by centrifugation. To obtain the membrane- and core-
enriched fractions, a protocol from Spencer, et al[14] was
modified. The equivalent of three tubes (or thirty 150 mm
dishes) was resuspended in 300 μL of buffer (0.8% OG,
50 mM DTT, 50 mM Tris, pH = 8.4). The three tubes con-
taining the pelleted virus were rinsed with another 300 μL
of buffer. The total 600 μL was placed in an incubator
shaker (New Brunswick, Innova 4300, Edison, NJ) for
1.25 hours, shaking at 200 rpm at 37°C. The sample was
centrifuged at 15,000 × g at 4°C for 15 min. The superna-
tant containing the enriched membrane fraction was
extracted leaving the pellet (enriched core fraction) intact.
HPLC (membrane-enriched fraction)
The sample was transferred into a dialysis cassette (Pierce,
Slide-A-Lyzer, 3,500 Da molecular weight cut off,
MWCO) and dialyzed against 800 mL of 20 mM Tris
(pH=8.0) for 2 hours at room temperature, and changed
three times. The final dialysis was performed for 16 hours
at 4°C. Dialysis was performed to remove as much of the
OG as possible. The sample was removed from the cas-
sette, reduced to 500 μL using a speed-vac, and filtered
through a 0.2 μ syringe filter. The sample was injected
onto an HPLC (Waters Breeze system, Milford, MA) using
a 500 μL sample loop. A 5 μm C4 300 Å 2 × 150 mm col-
umn (Phenomenex Jupiter, Torrance, CA) was used with
a flow rate of 0.2 mL/min. A wavelength absorbance
detector (Waters 2487 Dual Absorbance, Milford, MA)
was used to detect wavelengths at 214 and 254 nm. Sol-
vent A was composed of 5% AcN, 0.05% TFA in H2O and
solvent B was composed of 95% AcN, 0.05% TFA in H2O.
For the membrane-enriched sample the gradient system
consisted of 10 min isocratic gradient with 98% of solvent
A, 55 min gradient to 2% A, and 10 min isocratic gradient
with 2%. Fractions were collected in 5 minute intervals for
the first 20 min and then in 2 min intervals for 60 min.
The final 7 min was collected in one final fraction. A
speed-vac was used to decrease the volume of the fractions
to about 5–10 μL. The pH was adjusted with 50 mM Tris
(pH = 9.6) or N-ethylmorpholine to between 7.0 and 8.5.
For the trypsin digest 1.5 μL of trypsin (1 μg/μL, Promega,
Madison, WI) was added to each fraction. The fractions
were incubated overnight at 37°C.
HPLC (core-enriched fraction)
The core-enriched fraction was dissolved prior to injection
on the HPLC [12]. Briefly, this was carried out by resus-
pending the insoluble pellet from the virion fractionation
in 0.4% sodium deoxycholate and 10 mM Tris, pH = 9.0,
and incubating at 56°C for 10 min. The sample was fil-
tered and injected onto the HPLC system as described
above. For the core-enriched sample the gradient system
consisted of a 10 min isocratic gradient with 98% of sol-
vent A, 40 min gradient to 25%A, 30 min gradient to 2%
A, and a 10 min isocratic gradient with 2% A. Fractions
were collected as outlined above.
SDS-PAGE
Virion fractions were mixed with equal amounts of SDS-
PAGE loading buffer and resolved on SDS-PAGE gels
(12.5%) [15]. The protein bands were visualized using a
filtered Coomassie stain (40% methanol, 10% acetic acid
and 0.2% Coomassie brilliant blue R-250). Protein bands
were excised and the preparation for in-gel digestion [16]
Diagram of proteins identified using multiple methods Figure 6
Diagram of proteins identified using multiple meth-
ods. All overlaps are shown for all five methods: Method 1 - 
SDS-PAGE + LC-ESI-Q-TOF MS (dashed line); Method 2 - 
SDS-PAGE + LC-ESI-QIT MS (double line); Method 3 -HPLC 
+ LC-ESI-QIT MS (solid line); Method 4 - LC-ESI-Q-TOF MS 
(dotted line); and Method 5 - MALDI-TOF/TOF (triple line). 
Numbers represent the number of shared proteins in over-
lapping areas. The total number of proteins identified for the 
method and the percent of total proteins identified is listed.
Method 1
SDS-PAGE + 
LC-ESI-Q-TOF MS
49 proteins (77.8%)
Method 2
SDS-PAGE + 
LC-ESI-QIT MS
52 proteins (82.5%)
Method 3 
HPLC + LC-ESI-QIT MS
25 proteins (39.7%)
Method 4 
LC-ESI-Q-TOF MS
52 proteins (82.5%)
Method 5 MALDI-
TOF/TOF MS 
54 proteins (85.7%)
1
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1
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was as follows: sample bands from coomassie stained
were manually excised, and placed in 0.5 mL Eppendorf
tubes. The gel pieces were de-stained with acetic acid:eth-
anol:H2O in a 1:3:6 (v/v/v) ratio for 12–16 hours under
gentle agitation. The gel slices were dehydrated with AcN
(vortexed for 10 min), and re-hydrated with 50 mM
ammonium bicarbonate (vortexed for 10 min). This pro-
cedure was repeated twice, and a final dehydration was
performed with AcN. After vortexing any remaining liquid
was removed by pipette and the gel slices were dried with
a speed vac for 5 minutes.
In-gel trypsin digestion
To each tube containing gel slices 10–40 μL of 20 μg/μL
Promega trypsin in 25–50 mM Tris-HCl, pH = 8.0 was
added. The tubes were incubated on ice for 35–40 min.
After the enzyme solution was fully absorbed, the excess
solution was removed and replaced with 10 mM Tris-HCl,
pH = 8.0, enough to fully cover each gel slice. Each sample
was incubated at 37°C for 12–16 hours. Any non-
absorbed solution was placed in a new tube. The peptides
were extracted from the gel by vortexing with 30–70 μL of
50% AcN/5% formic acid. The extraction fluid was added
to the previously removed non-absorbed solution and
concentrated to 10–15 μL.
In-solution trypsin digestion
Samples from the HPLC or from the membrane-enriched
fraction were subjected to in-pot trypsin digest by adding
a 1:7 ratio of enzyme (1 μg/μL):protein and incubating at
37°C for 12–16 hours. Because the core-enriched fraction
contained an intact protein ''shell'' the following was con-
ducted in order to solubilize the proteins for trypsin diges-
tion. The pellet from the virion fractionation was
resuspended in 200 μL of 50 mM Tris (pH = 8.4), and 6 M
guanidine HCl. This solution was brought to 90°C for 5
minutes, and after the protein was dissolved, the mixture
was diluted with 2.8 mL of H20. Dialysis was performed
with a Slide-A-Lyzer (3,500 MWCO) membrane against
800 mL of 20 mM Tris-HCl (pH = 8.0). The buffer was
changed 3 times in 24 hours. As the guanidine HCl dia-
lyzed out of the protein solution the proteins precipitated
resulting a fluffy white precipitate. However, when this
solution was treated with trypsin (as outlined above) the
precipitate dissolved indicating that the trypsin cleaved
the proteins into various peptides.
LC-ESI-QIT MS
An electrospray ionization quadrupole ion trap mass
spectrometer (Finnigan LCQ, San Jose, CA) equipped
with a Waters (Milford, MA) 515 HPLC system and LC
Packings Accurate Flow Splitter was used. Ten microliters
of the tryptic digest was loaded on a C18 trap and a C18 col-
umn (0.17 × 10 mm, Jupiter 5 μ, 300 Å, packed in-house).
HPLC was performed with a gradient from 90% solvent A
(0.1% formic acid, 0.005% TFA, in 5% AcN) to 90% sol-
vent B (0.1% formic acid, 0.005% TFA in 95% AcN) over
60 minutes. The full mass spectra (m/z 400 to 2000) and
tandem MS (m/z 200 to 2000) spectra were acquired
alternately with a dynamic exclusion of 1 min and the
peptide was excluded for 1.5 min.
LC-ESI-Q-TOF MS
Five microliters of the tryptic digest sample was mixed
with 5 μL of solvent A (0.1% formic acid, 0.005% TFA,
and 3% AcN in H2O). Five microliters of this solution was
loaded for mass analysis. The HPLC was performed on a
Waters CapLC system with a flow rate of 300 nL/min in
conjunction with a Symmetry 300, C18, 5 μm trap from
Waters (Milford, MA) and a 15 cm long, 75 μm inner
diameter PicoFrit column from New Objective (Woburn,
MA) packed in-house with Jupiter C18 particles from Phe-
nomenex (Torrance, CA). The gradient program began
with 3% B (0.1% formic acid, 0.005% TFA in 90% AcN)
for 5 min to wash the sample, followed by a gradient up
to 30 % B over 40 min, to 50 % B at 60 min, to 70% B at
65 min, and held at 90% B from 70 to 78 min. The LC-ESI-
Q-TOF mass spectrometer (Global Ultima; Micromass,
Summary of the functions of the 63 identified VV proteins Figure 7
Summary of the functions of the 63 identified VV 
proteins. This graph summarizes the 63 VV proteins identi-
fied in this study according to their function. These include: 
core structural proteins (A3L, A4L, A10L, A12L, A14L, and 
L4R), membrane proteins (A13L, A17L, A27L, A33R, A34R, 
A56R, B5R, D8L, F9L, F13L, H3L, H5R, J1R, and L1R), tran-
scriptional proteins (A5R, A7L, A24R, A29L, D1R, D6R, 
D11L, D12L, E1L, E3L, E4L, H4L, I1L, I8R, J3R, J4R, J6R, and 
K4L), proteins with other functions (A15L, A16L, A30L, 
A42R, A46R, B22R, D2L, D3R, E8R, E10R, E11L, F8L, F10L, 
F17R, G1L, G3L, G4L, G7L, H1L, I3L, I5L, I7L, and O2L), and 
the unknown proteins (E6R and L3L).
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Ltd., Manchester, UK) was used with a spray voltage of 3.5
kV. The MS/MS data was recorded using a 0.5 sec MS sur-
vey scan and 2.5 sec MS/MS scans on the three most abun-
dant ions found in the survey scan. The CID energy was
between 25 and 65 eV depending on the mass and charge
state of the precursor ions.
MALDI-TOF/TOF MS
The in-pot tryptic digest sample was loaded on a Symme-
try 300 C18 trap and a 150 mm by 0.32 mm Symmetry col-
umn both packed with 5 μm C18 particles from Waters for
off-line HPLC separation before the mass analysis. The
same gradient was used as in the LC-ESI-Q-TOF MS with
solvent A (0.1% TFA and 1% AcN in H2O) and solvent B
(0.1% TFA and 1% H2O in AcN) with a flow rate of 3 μL/
min from a Waters CapLC system. The elutant from the
column was automatically mixed with 1 μL/min of 0.6
mg/mL HCCA and 0.08 mg/mL ammonium phosphate in
50:50 AcN:H2O containing 0.1% TFA. The sample was
passed through a 75 μm capillary at a combined rate of 4
μL/min into a Waters MALDIprep sprayer (Life Sciences R
& D Laboratory, Waters Corporation). A spotting time of
45 second per spot, a nitrogen flow rate of 7 psi, and a
temperature gradient of -2°C/7 min (65°C to 45°C over
90 min) was used. For MALDI tandem mass spectrometry
an Applied Biosystems 4700 proteomics Analyzer
(Applied Biosystem, Inc., Framingham, MA) was used. MS
data were acquired using the reflector mode. Ten tandem
mass spectra were recorded from each spot. Ions with a
signal to noise (S/N) ration greater than 30 were chosen
for tandem mass spectrometry. The tandem mass spectra
were recorded by accelerating the precursor ions to 8 keV,
selecting with the timed gate set to 3 Da, and performing
the collision induced dissociation (CID) at 1 keV. The gas
pressure (air) in the CID cell was at 6 × 10-7 Torr and the
fragment ions were accelerated to 14 keV before entering
the reflector.
Data Analysis
Mascot (Matrix Science, London, UK) software was used
for the protein identification. The uninterpreted tandem
mass spectral data were searched against a VV protein
database created in-house based on the complete DNA
sequence of vaccinia virus (PUBMED 2219722). Specifi-
cally, 273 protein sequences in FASTA format were organ-
ized and loaded onto the in-house Mascot primary
sequence database. All MS data was also searched against
the MSDB database, a composite, non-identical protein
sequence database built from a number of primary source
databases (Matrix Science). The LC-ESI-QIT MS data was
converted into Sequest DTA files and searched with the
Mascot program.
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